[go: up one dir, main page]

US20150239848A1 - Enzalutamide polymorphic forms and its preparation - Google Patents

Enzalutamide polymorphic forms and its preparation Download PDF

Info

Publication number
US20150239848A1
US20150239848A1 US14/427,527 US201314427527A US2015239848A1 US 20150239848 A1 US20150239848 A1 US 20150239848A1 US 201314427527 A US201314427527 A US 201314427527A US 2015239848 A1 US2015239848 A1 US 2015239848A1
Authority
US
United States
Prior art keywords
enzalutamide
solvent
less
crystalline
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/427,527
Other languages
English (en)
Inventor
Vishweshwar Peddy
Rajesham Boge
Lokeswara Rao Madivada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Reddys Laboratories Ltd
Original Assignee
Dr Reddys Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Reddys Laboratories Ltd filed Critical Dr Reddys Laboratories Ltd
Publication of US20150239848A1 publication Critical patent/US20150239848A1/en
Assigned to DR. REDDY'S LABORATORIES LIMITED reassignment DR. REDDY'S LABORATORIES LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BOGE, RAJESHAM, MADIVADA, LOKESWARA RAO, PEDDY, VISHWESHWAR
Abandoned legal-status Critical Current

Links

Images

Classifications

    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W12/00—Security arrangements; Authentication; Protecting privacy or anonymity
    • H04W12/06—Authentication
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L65/00—Network arrangements, protocols or services for supporting real-time applications in data packet communication
    • H04L65/10—Architectures or entities
    • H04L65/1016—IP multimedia subsystem [IMS]
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L65/00—Network arrangements, protocols or services for supporting real-time applications in data packet communication
    • H04L65/1066—Session management
    • H04L65/1073—Registration or de-registration
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L65/00—Network arrangements, protocols or services for supporting real-time applications in data packet communication
    • H04L65/40—Support for services or applications
    • H04L65/4061—Push-to services, e.g. push-to-talk or push-to-video
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L9/00—Cryptographic mechanisms or cryptographic arrangements for secret or secure communications; Network security protocols
    • H04L9/40—Network security protocols
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W12/00—Security arrangements; Authentication; Protecting privacy or anonymity
    • H04W12/06—Authentication
    • H04W12/069—Authentication using certificates or pre-shared keys
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W12/00—Security arrangements; Authentication; Protecting privacy or anonymity
    • H04W12/08—Access security
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W12/00—Security arrangements; Authentication; Protecting privacy or anonymity
    • H04W12/08—Access security
    • H04W12/086—Access security using security domains
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/06—Selective distribution of broadcast services, e.g. multimedia broadcast multicast service [MBMS]; Services to user groups; One-way selective calling services
    • H04W4/10—Push-to-Talk [PTT] or Push-On-Call services
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/90—Services for handling of emergency or hazardous situations, e.g. earthquake and tsunami warning systems [ETWS]
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W60/00—Affiliation to network, e.g. registration; Terminating affiliation with the network, e.g. de-registration
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W60/00—Affiliation to network, e.g. registration; Terminating affiliation with the network, e.g. de-registration
    • H04W60/005—Multiple registrations, e.g. multihoming
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W76/00—Connection management
    • H04W76/40—Connection management for selective distribution or broadcast
    • H04W76/45—Connection management for selective distribution or broadcast for Push-to-Talk [PTT] or Push-to-Talk over cellular [PoC] services
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W76/00—Connection management
    • H04W76/50—Connection management for emergency connections

Definitions

  • aspects of the present application relate to polymorphic forms of enzalutamide which are useful in making pharmaceutically acceptable dosage forms, and processes for its preparation.
  • the drug compound having the adopted name enzalutamide has a chemical name 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide, and is represented by structure of formula
  • Enzalutamide is an oral, once-daily investigational agent that is an androgen receptor signaling inhibitor used for the potential treatment of men with castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy.
  • Enzalutamide inhibits androgen receptor signaling in three distinct ways: it inhibits 1) testosterone binding to androgen receptors; 2) nuclear translocation of androgen receptors; and 3) DNA binding and activation by androgen receptors.
  • U.S. Pat. No. 7,709,517 discloses enzalutamide, method of use and it's pharmaceutically composition.
  • polymorphic forms can vary in their physical properties, regulatory authorities require that efforts shall be made to identify all polymorphic forms, e.g., crystalline, amorphous, solvated, etc., of new drug substances.
  • polymorphic forms for a given compound cannot be predicted, and there are no “standard” procedures that can be used to prepare polymorphic forms of a substance.
  • new forms of a pharmaceutically useful compound may provide an opportunity to improve the performance characteristics of pharmaceutical products. For example, in some cases, different forms of the same drug can exhibit very different solubility and dissolution rates.
  • the discovery of new polymorphic forms enlarges selection of materials with which formulation scientists can design a pharmaceutically acceptable dosage form of a drug with a targeted release profile or other desired characteristics. Therefore, there remains a need for preparing new and stable polymorphic forms of enzalutamide.
  • the present application provides crystalline enzalutamide Form R1 characterized by its powder X-ray diffraction (PXRD) pattern having one or more peaks at about 12.3 ⁇ 0.2, 13.1 ⁇ 0.2, 15.0 ⁇ 0.2, and 17.5 ⁇ 0.2 degrees 2-theta.
  • PXRD powder X-ray diffraction
  • the present invention provides crystalline enzalutamide Form R1 further characterized by the powder X-ray diffraction pattern having one or more additional peaks at about 9.8 ⁇ 0.2, 13.5 ⁇ 0.2, 14.3 ⁇ 0.2, 16.7 ⁇ 0.2, 18.9 ⁇ 0.2, 21.1 ⁇ 0.2, 21.8 ⁇ 0.2, 22.8 ⁇ 0.2 and 24.4 ⁇ 0.2 degrees 2-theta.
  • the present invention provides crystalline form R1 of enzalutamide characterized by a PXRD pattern substantially as illustrated by FIG. 1 .
  • the present application provides a process for the preparation of crystalline enzalutamide Form R1, comprising:
  • the present application provides crystalline enzalutamide Form R2 characterized by its powder X-ray diffraction (PXRD) pattern having one or more peaks at about 4.8 ⁇ 0.2, 11.3 ⁇ 0.2 and 20.2 ⁇ 0.2 degrees 2-theta.
  • PXRD powder X-ray diffraction
  • the present invention provides crystalline enzalutamide Form R2 further characterized by the powder X-ray diffraction pattern having one or more additional peaks at about 9.7 ⁇ 0.2, 14.5 ⁇ 0.2, 15.6 ⁇ 0.2, 16.9 ⁇ 0.2 and 25.5 ⁇ 0.2 degrees 2-theta.
  • the present invention provides crystalline form R2 of enzalutamide characterized by a PXRD pattern substantially as illustrated by FIG. 2 .
  • the present application provides a process for the preparation of crystalline enzalutamide Form R2, comprising:
  • the present application provides an amorphous form of enzalutamide.
  • the present application provides a process for the preparation of amorphous form of enzalutamide, comprising:
  • the present application provides solid dispersion comprising enzalutamide, together with one or more pharmaceutically acceptable excipients.
  • the present application provides a process for preparing a solid dispersion of amorphous enzalutamide together with one or more pharmaceutically acceptable carriers, comprising
  • the present application provides pharmaceutical formulations comprising crystalline Form R1, crystalline Form R2 or amorphous form of enzalutamide or mixtures thereof together with one or more pharmaceutically acceptable excipients.
  • FIG. 1 illustrates the PXRD pattern of crystalline enzalutamide Form R1 obtained by the procedure of Example 1.
  • FIG. 2 illustrates the PXRD pattern of crystalline enzalutamide Form R2 obtained by the procedure of Example 26.
  • FIG. 3 illustrates the PXRD pattern of amorphous enzalutamide, obtained by the procedure of Example 29.
  • FIG. 4 illustrates the PXRD pattern of amorphous enzalutamide, obtained by the procedure of Example 30.
  • the present application provides crystalline enzalutamide Form R1 characterized by its powder X-ray diffraction (PXRD) pattern having one or more peaks at about 12.3 ⁇ 0.2, 13.1 ⁇ 0.2, 15.0 ⁇ 0.2, and 17.5 ⁇ 0.2 degrees 2-theta.
  • PXRD powder X-ray diffraction
  • the present invention provides crystalline enzalutamide Form R1 further characterized by the powder X-ray diffraction pattern having additional peaks at about 9.8 ⁇ 0.2, 13.5 ⁇ 0.2, 14.3 ⁇ 0.2, 16.7 ⁇ 0.2, 18.9 ⁇ 0.2, 21.1 ⁇ 0.2, 21.8 ⁇ 0.2, 22.8 ⁇ 0.2 and 24.4 ⁇ 0.2 degrees 2-theta.
  • the present invention provides crystalline form R1 of enzalutamide characterized by a PXRD pattern substantially as illustrated by FIG. 1 .
  • the present application provides a process for the preparation of crystalline enzalutamide Form R1, comprising:
  • Providing a solution in step a) includes:
  • enzalutamide Any physical form of enzalutamide may be utilized for providing the solution of enzalutamide in step a).
  • a water reduction or removal step may be carried out by the techniques known in the art such as distillation, heating, slurrying in a suitable solvent and the like.
  • enzalutamide obtained in the course of its synthesis can be dissolved in any suitable solvent.
  • suitable solvents include, but are not limited to: alcohols, such as C 2 -C 6 alcohols like ethanol, 1-propanol, 2-propanol (isopropyl alcohol), 1-butanol, 2-butanol, t-butyl alcohol; or nitriles, such as acetonitrile or propionitrile; amides such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methyl-2-pyrrolidone; sulfoxides such as dimethylsulfoxide; halogenated hydrocarbons such as dichloromethane; aromatic hydrocarbons such as toluene, xylene; esters such as ethyl acetate, n-propyl acetate, n-butyl acetate, isopropyl acetate, isobutyl acetate, t-
  • the dissolution temperatures may range from about 0° C. to about the reflux temperature of the solvent, or less than about 150° C., less than about 130° C., less than about 100° C., less than about 70° C., less than about 40° C., less than about 20° C., less than about 0° C., or any other suitable temperatures, as long as a clear solution of enzalutamide is obtained without affecting its quality.
  • the solution may optionally be treated with carbon, flux-calcined diatomaceous earth (Hyflow) or any other suitable material to remove color, insoluble materials, improve clarity of the solution, and/or remove impurities adsorbable on such material.
  • the solution obtained above may be filtered to remove any insoluble particles.
  • the insoluble particles may be removed suitably by filtration, centrifugation, decantation, or any other suitable techniques under pressure or under reduced pressure.
  • the solution may be filtered by passing through paper, glass fiber, cloth or other membrane material, or a bed of a clarifying agent such as Celite® or Hyflow.
  • the filtration apparatus may need to be preheated to avoid premature crystallization.
  • Step b) involves isolating crystalline enzalutamide Form R1 from the solution obtained in step a).
  • Isolation of crystalline enzalutamide Form R1 in step b) is carried out by methods including cooling, crash cooling, concentrating the mass, adding an anti-solvent, adding seed crystals to induce crystallization or evaporation or the like or combinations thereof. Stirring or other alternate methods such as shaking, agitation, or the like, may also be employed for the isolation.
  • crystals of Form R1 are present in the solution obtained in step (a)
  • those crystals may act as seed crystals and Form R1 can be isolated in presence of such seed crystals of Form R1 in step (b).
  • isolation may be effected by combining a suitable anti-solvent with the solution obtained in step a).
  • Anti-solvent refers to a liquid in which enzalutamide is less soluble or poorly soluble. An anti-solvent has no adverse effect on the quality of enzalutamide and it can assist in the solidification or precipitation of the dissolved starting material.
  • Suitable anti-solvents include, but are not limited to: water, saturated or unsaturated, linear or branched, cyclic or acyclic, C 1 to C 10 hydrocarbons, such as hexanes, heptane, cyclohexane, or methylcyclohexane; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran, dioxane, or dimethoxyethane; or mixtures thereof.
  • Suitable temperatures for isolation may be less than about 100° C., less than about 80° C., less than about 60° C., less than about 40° C., less than about 20° C., less than about 10° C., less than about 5° C., less than about 0° C., less than about ⁇ 10° C., less than about ⁇ 20° C., or any other suitable temperatures.
  • the isolated crystalline enzalutamide Form R1 may be recovered by methods including decantation, centrifugation, evaporation, gravity filtration, suction filtration, or any other technique for the recovery of solids under pressure or under reduced pressure.
  • the recovered solid may optionally be dried. Drying may be carried out in a tray dryer, vacuum oven, air oven, cone vacuum dryer, rotary vacuum dryer, fluidized bed dryer, spin flash dryer, flash dryer, or the like.
  • the drying may be carried out at temperatures less than about 100° C., less than about 80° C., less than about 60° C., less than about 50° C., less than about 30° C., or any other suitable temperatures, at atmospheric pressure or under a reduced pressure, as long as the enzalutamide is not degraded in quality.
  • the drying may be carried out for any desired times until the required product quality is achieved.
  • the dried product may optionally be subjected to a size reduction procedure to produce desired particle sizes. Milling or micronization may be performed before drying, or after the completion of drying of the product. Techniques that may be used for particle size reduction include, without limitation, ball, roller and hammer milling, and jet milling.
  • the present application provides crystalline enzalutamide Form R2 characterized by its powder X-ray diffraction (PXRD) pattern having one or more peaks at about 4.8 ⁇ 0.2, 11.3 ⁇ 0.2 and 20.2 ⁇ 0.2 degrees 2-theta.
  • PXRD powder X-ray diffraction
  • the present invention provides crystalline enzalutamide Form R2 further characterized by the powder X-ray diffraction pattern having one or more additional peaks at about 9.7 ⁇ 0.2, 14.5 ⁇ 0.2, 15.6 ⁇ 0.2, 16.9 ⁇ 0.2 and 25.5 ⁇ 0.2 degrees 2-theta.
  • the present invention provides crystalline form R2 of enzalutamide characterized by a PXRD pattern substantially as illustrated by FIG. 2 .
  • the present application provides a process for the preparation of crystalline enzalutamide Form R2, comprising:
  • Providing a solution in step a) includes:
  • enzalutamide Any physical form of enzalutamide may be utilized for providing the solution of enzalutamide in step a).
  • a water reduction or removal step may be carried out by the techniques known in the art such as distillation, heating, slurrying in a suitable solvent and the like.
  • enzalutamide obtained in the course of its synthesis can be dissolved in methanol or formic acid; or any mixtures thereof.
  • the dissolution temperatures may range from about 0° C. to about the reflux temperature of the solvent, or less than about 100° C., less than about 80° C., less than about 60° C., less than about 40° C., less than about 20° C., less than about 10° C., or any other suitable temperatures, as long as a clear solution of enzalutamide is obtained without affecting its quality.
  • the solution may optionally be treated with carbon, flux-calcined diatomaceous earth (Hyflow) or any other suitable material to remove color, insoluble materials, improve clarity of the solution, and/or remove impurities adsorbable on such material.
  • the solution obtained above may be filtered to remove any insoluble particles.
  • the insoluble particles may be removed suitably by filtration, centrifugation, decantation, or any other suitable techniques under pressure or under reduced pressure.
  • the solution may be filtered by passing through paper, glass fiber, cloth or other membrane material, or a bed of a clarifying agent such as Celite® or Hyflow.
  • the filtration apparatus may need to be preheated to avoid premature crystallization.
  • Step b) involves isolating crystalline enzalutamide Form R2 from the solution obtained in step a).
  • Isolation of crystalline enzalutamide Form R2 in step b) may involve methods including cooling, concentrating the mass, adding an anti-solvent, adding seed crystals to induce crystallization or the like. Stirring or other alternate methods such as shaking, agitation, or the like, may also be employed for the isolation.
  • isolation may be effected by combining a suitable anti-solvent with the solution obtained in step a).
  • Anti-solvent refers to a liquid in which enzalutamide is less soluble or poorly soluble. An anti-solvent has no adverse effect on the quality of enzalutamide and it can assist in the solidification or precipitation of the dissolved starting material.
  • Suitable anti-solvents include, but are not limited to: saturated or unsaturated, linear or branched, cyclic or acyclic, C 1 to C 10 hydrocarbons, such as hexanes, heptane, cyclohexane, or methylcyclohexane; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran, dioxane, or dimethoxyethane; or any mixtures thereof.
  • Suitable temperatures for isolation may be less than about 100° C., less than about 80° C., less than about 60° C., less than about 40° C., less than about 20° C., less than about 10° C., less than about 5° C., less than about 0° C., less than about ⁇ 10° C., less than about ⁇ 20° C., or any other suitable temperatures.
  • the isolated crystalline enzalutamide Form R2 may be recovered by methods including decantation, centrifugation, gravity filtration, suction filtration, or any other technique for the recovery of solids under pressure or under reduced pressure.
  • the recovered solid may optionally be dried. Drying may be carried out in a tray dryer, vacuum oven, air oven, cone vacuum dryer, rotary vacuum dryer, fluidized bed dryer, spin flash dryer, flash dryer, or the like. The drying may be carried out at temperatures less than about 100° C., less than about 80° C., less than about 60° C., less than about 50° C., less than about 30° C., or any other suitable temperatures, at atmospheric pressure or under a reduced pressure, as long as the enzalutamide is not degraded in quality.
  • the drying may be carried out for any desired times until the required product quality is achieved.
  • the dried product may optionally be subjected to a size reduction procedure to produce desired particle sizes. Milling or micronization may be performed before drying, or after the completion of drying of the product. Techniques that may be used for particle size reduction include, without limitation, ball, roller and hammer milling, and jet milling.
  • the present application provides a process for the preparation of amorphous form of enzalutamide, comprising:
  • Providing a solution of enzalutamide in step a) includes:
  • any physical form of enzalutamide may be utilized for providing the solution of enzalutamide in step a).
  • the dissolution temperatures may range from about 0° C. to about the reflux temperature of the solvent, or less than about 60° C., less than about 50° C., less than about 40° C., less than about 30° C., less than about 20° C., less than about 10° C., or any other suitable temperatures, as long as a clear solution of enzalutamide is obtained without affecting its quality.
  • the solution may optionally be treated with carbon, flux-calcined diatomaceous earth (Hyflow) or any other suitable material to remove color, insoluble materials, improve clarity of the solution, and/or remove impurities adsorbable on such material.
  • the solution obtained above may be filtered to remove any insoluble particles.
  • the insoluble particles may be removed suitably by filtration, centrifugation, decantation, or any other suitable techniques under pressure or under reduced pressure.
  • the solution may be filtered by passing through paper, glass fiber, cloth or other membrane material, or a bed of a clarifying agent such as Celite® or Hyflow.
  • the filtration apparatus may need to be preheated to avoid premature crystallization.
  • enzalutamide can be dissolved in any suitable solvent.
  • suitable solvents include any solvents that have no adverse effect on the compound and can dissolve the starting material to a useful extent.
  • solvents include, but are not limited to: ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran, dioxane, or dimethoxyethane; ketones, such as acetone, methyl ethyl ketone, methyl isobutyl ketone, or diethyl ketone; esters, such as ethyl acetate, propyl acetate, isopropyl acetate, or butyl acetate; alcohols, such as methanol, ethanol, 1-propanol, 2-propanol (isopropyl alcohol), 2-methoxyethanol, 1-butanol, 2-butanol, iso-butyl alcohol, t-butyl alcohol, 2-ethoxyethanol,
  • Step b) involves isolating amorphous form of enzalutamide from the solution obtained in step a).
  • Isolation of amorphous form of enzalutamide in step b) may involve methods including removal of solvent, cooling, crash cooling, concentrating the mass, evaporation, flash evaporation, simple evaporation, rotational drying, spray drying, thin-film drying, agitated nutsche filter drying, pressure nutsche filter drying, freeze-drying, adding anti-solvent, extraction with a solvent, adding seed to induce isolation, or the like.
  • Stirring or other alternate methods such as shaking, agitation, or the like, may also be employed for the isolation.
  • the amorphous form of enzalutamide as isolated may carry some amount of occluded mother liquor and may have higher than desired levels of impurities. If desired, this amorphous form may be washed with a solvent or a mixture of solvents to wash out the impurities.
  • Suitable temperatures for isolation may be less than about 120° C., less than about 80° C., less than about 60° C., less than about 40° C., less than about 30° C., less than about 20° C., less than about 10° C., less than about 0° C., less than about ⁇ 10° C., less than about ⁇ 40° C. or any other suitable temperatures.
  • isolation may be effected by combining a suitable anti-solvent with the solution obtained in step a).
  • Anti-solvent refers to a liquid in which enzalutamide is less soluble or poorly soluble.
  • An inert anti-solvent has no adverse effect on the reaction and it can assist in the solidification or precipitation of the dissolved starting material.
  • Suitable anti-solvents include, but are not limited to: saturated or unsaturated, linear or branched, cyclic or acyclic, C 1 to C 10 hydrocarbons, such as heptanes, cyclohexane, or methylcyclohexane; water; or any mixtures thereof.
  • the recovered solid may optionally be dried. Drying may be carried out in a tray dryer, vacuum oven, air oven, cone vacuum dryer, rotary vacuum dryer, fluidized bed dryer, spin flash dryer, flash dryer, or the like. The drying may be carried out at temperatures less than about 100° C., less than about 80° C., less than about 60° C., less than about 50° C., less than about 30° C., or any other suitable temperatures, at atmospheric pressure or under a reduced pressure, as long as the enzalutamide is not degraded in quality. The drying may be carried out for any desired times until the required product quality is achieved. The dried product may optionally be subjected to a size reduction procedure to produce desired particle sizes. Milling or micronization may be performed before drying, or after the completion of drying of the product. Techniques that may be used for particle size reduction include, without limitation, ball, roller or hammer milling; or jet milling.
  • the present application provides amorphous solid dispersion comprising enzalutamide, together with one or more pharmaceutically acceptable excipients.
  • the present application provides a process for preparing a solid dispersion of amorphous enzalutamide together with one or more pharmaceutically acceptable carriers, comprising
  • Step a) involves providing a solution of enzalutamide in combination with at least one pharmaceutically acceptable carrier, in a suitable solvent or mixture of solvents;
  • Step a) may involve forming a solution of enzalutamide together with one or more pharmaceutically acceptable carriers.
  • a carrier enhances stability of the amorphous solid upon removal of solvent.
  • Providing the solution in step a) includes:
  • reaction mixture containing enzalutamide that is obtained in the course of its manufacture, if desired, after addition of one or more pharmaceutically acceptable carriers;
  • any physical form of enzalutamide such as crystalline, amorphous or their mixtures may be utilized for providing a solution in step a).
  • Pharmaceutically acceptable carriers that may be used in step a) include, but are not limited to: diluents such as starches, pregelatinized starches, lactose, powdered celluloses, microcrystalline celluloses, dicalcium phosphate, tricalcium phosphate, mannitol, sorbitol, sugar, or the like; binders such as acacia, guar gum, tragacanth, gelatin, polyvinylpyrrolidones, hydroxypropyl celluloses, hydroxypropyl methyl celluloses, pregelatinized starches, or the like; disintegrants such as starches, sodium starch glycolate, pregelatinized starches, crospovidones, croscarmellose sodium, colloidal silicon dioxide, or the like; lubricants such as stearic acid, magnesium stearate, zinc stearate, or the like; glidants such as colloidal silicon dioxide or the like; solubility or wetting enhancers such as ani
  • the dissolution temperatures may range from about 0° C. to about the reflux temperature of the solvent, or less than about 60° C., less than about 50° C., less than about 40° C., less than about 30° C., less than about 20° C., less than about 10° C., or any other suitable temperatures, as long as a clear solution of enzalutamide is obtained without affecting its quality.
  • the solution may optionally be treated with carbon, flux-calcined diatomaceous earth (Hyflow) or any other suitable material to remove color, insoluble materials, improve clarity of the solution, and/or remove impurities adsorbable on such material.
  • the solution obtained above may be filtered to remove any insoluble particles.
  • the insoluble particles may be removed suitably by filtration, centrifugation, decantation, or any other suitable techniques under pressure or under reduced pressure.
  • the solution may be filtered by passing through paper, glass fiber, cloth or other membrane material, or a bed of a clarifying agent such as Celite® or Hyflow.
  • the filtration apparatus may need to be preheated to avoid premature crystallization.
  • Suitable solvents that may be used in step a) include but are not limited to: ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran, dioxane, or dimethoxyethane; ketones, such as acetone, methyl ethyl ketone, methyl isobutyl ketone, or diethyl ketone; esters, such as ethyl acetate, propyl acetate, isopropyl acetate, or butyl acetate; alcohols, such as methanol, ethanol, 2-nitroethanol, 2-fluoroethanol, ethylene glycol, 1-propanol, 2-propanol (isopropyl alcohol), 2-methoxyethanol, 1-butanol, 2-butanol, iso-butyl alcohol, t-butyl alcohol, 2-ethoxyethanol, neo-pentyl alcohol, t-pentyl alcohol, diethylene glycol
  • Step b) involves isolating a solid dispersion of amorphous enzalutamide together with one or more pharmaceutically acceptable carriers.
  • Isolation of solid dispersion of amorphous form of enzalutamide in step b) may involve methods including removal of solvent, cooling, crash cooling, concentrating the mass, evaporation, flash evaporation, simple evaporation, rotational drying, spray drying, thin-film drying, agitated nutsche filter drying, pressure nutsche filter drying, freeze-drying, adding anti-solvent, extraction with a solvent, adding seed to induce isolation, or the like. Stirring or other alternate methods such as shaking, agitation, or the like, may also be employed for the isolation.
  • the amorphous form of enzalutamide as isolated may carry some amount of occluded mother liquor and may have higher than desired levels of impurities. If desired, this amorphous form may be washed with a solvent or a mixture of solvents to wash out the impurities.
  • Suitable temperatures for isolation may be less than about 120° C., less than about 80° C., less than about 60° C., less than about 40° C., less than about 30° C., less than about 20° C., less than about 10° C., less than about 0° C., less than about ⁇ 10° C., less than about ⁇ 40° C. or any other suitable temperatures.
  • isolation may be effected by combining a suitable anti-solvent with the solution obtained in step a).
  • Anti-solvent refers to a liquid in which enzalutamide is less soluble or poorly soluble.
  • An inert anti-solvent has no adverse effect on the reaction and it can assist in the solidification or precipitation of the dissolved starting material.
  • Suitable anti-solvents include, but are not limited to: saturated or unsaturated, linear or branched, cyclic or acyclic, C 1 to C 10 hydrocarbons, such as heptanes, cyclohexane, or methylcyclohexane; water; or any mixtures thereof.
  • the recovered solid may optionally be dried. Drying may be carried out in a tray dryer, vacuum oven, air oven, cone vacuum dryer, rotary vacuum dryer, fluidized bed dryer, spin flash dryer, flash dryer, or the like. The drying may be carried out at temperatures less than about 100° C., less than about 80° C., less than about 60° C., less than about 50° C., less than about 30° C., or any other suitable temperatures, at atmospheric pressure or under a reduced pressure, as long as the enzalutamide is not degraded in quality. The drying may be carried out for any desired times until the required product quality is achieved. The dried product may optionally be subjected to a size reduction procedure to produce desired particle sizes. Milling or micronization may be performed before drying, or after the completion of drying of the product. Techniques that may be used for particle size reduction include, without limitation, ball, roller or hammer milling; or jet milling.
  • Crystalline enzalutamide Form R1, crystalline enzalutamide Form R2, amorphous form of enzalutamide or a solid dispersion of enzalutamide together with one or more pharmaceutically acceptable excipients of the present application may be further formulated as: solid oral dosage forms such as, but not limited to: powders, granules, pellets, tablets, and capsules; liquid oral dosage forms such as but not limited to syrups, suspensions, dispersions, and emulsions; and injectable preparations such as but not limited to solutions, dispersions, and freeze dried compositions. Formulations may be in the forms of immediate release, delayed release or modified release.
  • immediate release compositions may be conventional, dispersible, chewable, mouth dissolving, or flash melt preparations, and modified release compositions that may comprise hydrophilic or hydrophobic, or combinations of hydrophilic and hydrophobic, release rate controlling substances to form matrix or reservoir or combination of matrix and reservoir systems.
  • the compositions may be prepared using techniques such as direct blending, dry granulation, wet granulation, and extrusion and spheronization.
  • Compositions may be presented as uncoated, film coated, sugar coated, powder coated, enteric coated, and modified release coated.
  • Compositions of the present application may further comprise one or more pharmaceutically acceptable excipients.
  • compositions that are useful in the present application include, but are not limited to: diluents such as starches, pregelatinized starches, lactose, powdered celluloses, microcrystalline celluloses, dicalcium phosphate, tricalcium phosphate, mannitol, sorbitol, sugar and the like; binders such as acacia, guar gum, tragacanth, gelatin, polyvinylpyrrolidones, hydroxypropyl celluloses, hydroxypropyl methylcelluloses, pregelatinized starches and the like; disintegrants such as starches, sodium starch glycolate, pregelatinized starches, crospovidones, croscarmellose sodium, colloidal silicon dioxide and the like; lubricants such as stearic acid, magnesium stearate, zinc stearate and the like; glidants such as colloidal silicon dioxide and the like; solubility or wetting enhancers such as anionic or cationic
  • Polymorphic forms are characterized by scattering techniques, e.g., x-ray powder diffraction pattern, by spectroscopic methods, e.g., infra-red, 13 C nuclear magnetic resonance spectroscopy, and by thermal techniques, e.g., differential scanning calorimetry or differential thermal analysis.
  • the compound of this application is best characterized by the X-ray powder diffraction pattern determined in accordance with procedures that are known in the art. For a discussion of these techniques see J. Haleblian, J. Pharm. Sci. 1975 64:1269-1288, and J. Haleblian and W. McCrone, J. Pharm. Sci. 1969 58:911-929.
  • Crystal forms of the application can be further processed to modulate particle size. For example, the crystal forms of the application can be milled to reduce average crystal size and/or to prepare a sample suitable for manipulation and formulation.
  • a diffraction angle (20) in powder X-ray diffractometry may have an error in the range of ⁇ 0.2°. Therefore, the aforementioned diffraction angle values should be understood as including values in the range of about ⁇ 0.2°. Accordingly, the present application includes not only crystals whose peak diffraction angles in powder X-ray diffractometry completely coincide with each other, but also crystals whose peak diffraction angles coincide with each other with an error of about ⁇ 0.2°. Therefore, in the present specification, the phrase “having a diffraction peak at a diffraction angle (2 ⁇ 0.2°) of 7.9°” means “having a diffraction peak at a diffraction angle (2 ⁇ ) of 7.7° to 8.1°.
  • the intensities of peaks in the x-ray powder diffraction patterns of different batches of a compound may vary slightly, the peaks and the peak locations are characteristic for a specific polymorphic form. Alternatively, the term “about” means within an acceptable standard error of the mean, when considered by one of ordinary skill in the art.
  • the relative intensities of the XRD peaks can vary depending on the sample preparation technique, crystal size distribution, various filters used, the sample mounting procedure, and the particular instrument employed. Moreover, instrument variation and other factors can affect the 2-theta values. Therefore, the term “substantially” in the context of XRD is meant to encompass that peak assignments can vary by plus or minus about 0.2 degree.
  • anti-solvent refers to a liquid that, when combined with a solution of enzalutamide, reduces solubility of the enzalutamide in the solution, causing crystallization or precipitation in some instances spontaneously, and in other instances with additional steps, such as aging, seeding, cooling, scratching and/or concentrating.
  • Celite® is flux-calcined diatomaceous earth.
  • Celite® is a registered trademark of World Minerals Inc.
  • Hyflow is flux-calcined diatomaceous earth treated with sodium carbonate.
  • Hyflo Super CelTM is a registered trademark of the Manville Corp. Polymorphs are different solids having the same molecular structure, yet having distinct physical properties when compared to other polymorphs of the same structure.
  • C 1 -C 6 alcohols include, but are not limited to, methanol, ethanol, 2-nitroethanol, 2-fluoroethanol, 2,2,2-trifluoroethanol, hexafluoroisopropyl alcohol, ethylene glycol, 1-propanol, 2-propanol (isopropyl alcohol), 2-methoxyethanol, 1-butanol, 2-butanol, i-butyl alcohol, t-butyl alcohol, 2-ethoxyethanol, diethylene glycol, 1-, 2-, or 3-pentanol, neo-pentyl alcohol, t-pentyl alcohol, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, cyclohexanol, phenol, glycerol, or the like.
  • aliphatic or alicyclic hydrocarbon solvent refers to a liquid, non-aromatic, hydrocarbon, which may be linear, branched, or cyclic. It is capable of dissolving a solute to form a uniformly dispersed solution.
  • hydrocarbon solvent examples include, but are not limited to, n-pentane, isopentane, neopentane, n-hexane, isohexane, 3-methylpentane, 2,3-dimethylbutane, neohexane, n-heptane, isoheptane, 3-methylhexane, neoheptane, 2,3-dimethylpentane, 2,4-dimethylpentane, 3,3-dimethylpentane, 3-ethylpentane, 2,2,3-trimethylbutane, n-octane, isooctane, 3-methylheptane, neooctane, cyclohexane, methylcyclohexane, cycloheptane, C 5 -C 8 aliphatic hydrocarbons, ligroin, petroleum ethers, or mixtures thereof.
  • Aromatic hydrocarbon solvent refers to a liquid, unsaturated, cyclic, hydrocarbon containing one or more rings which has at least one 6-carbon ring containing three double bonds. It is capable of dissolving a solute to form a uniformly dispersed solution.
  • aromatic hydrocarbon solvent include, but are not limited to, benzene toluene, ethylbenzene, m-xylene, o-xylene, p-xylene, indane, naphthalene, tetralin, trimethylbenzene, chlorobenzene, fluorobenzene, trifluorotoluene, anisole, C 8 -C 10 aromatic hydrocarbons, or mixtures thereof.
  • ether solvent is an organic solvent containing an oxygen atom —O— bonded to two other carbon atoms.
  • “Ether solvents” include but are not limited to diethyl ether, diisopropyl ether, methyl t-butyl ether, glyme, diglyme, tetrahydrofuran, 1,4-dioxane, dibutyl ether, dimethylfuran, 2-methoxyethanol, 2-ethoxyethanol, anisole, C 2-6 ethers, or the like.
  • esters are an organic compound containing a carboxyl group —(C ⁇ O)—O-bonded to two other carbon atoms.
  • C 3 -C 6 esters include, but are not limited to, ethyl acetate, n-propyl acetate, n-butyl acetate, isobutyl acetate, t-butyl acetate, ethyl formate, methyl acetate, methyl propanoate, ethyl propanoate, methyl butanoate, ethyl butanoate, or the like.
  • a “ketone” is an organic compound containing a carbonyl group —(C ⁇ O)-bonded to two other carbon atoms.
  • C 3 -C 6 ketones include, but are not limited to, acetone, ethyl methyl ketone, diethyl ketone, methyl isobutyl ketone, ketones, or the like.
  • a “nitrile” is an organic compound containing a cyano —(C ⁇ N) bonded to another carbon atom.
  • C 2 -C 6 Nitriles include, but are not limited to, acetonitrile, propionitrile, butanenitrile, or the like.
  • the Powder X-ray diffraction (PXRD) pattern of enzalutamide obtained in above example is in accordance with FIG. 1 .
  • Enzalutamide (100 mg) and acetic acid (1 mL) was charged into a round bottom flask at 26° C. and stirred for 5 minutes. Water (10 mL) was added to the resultant reaction mass at 26° C. and stirred at 26° C. for 15 minutes. Separated solid was collected by filtration and dried at 50° C. under reduced pressure for 1 hour to afford the title compound.
  • Enzalutamide (200 mg) charged into a flask at 26° C. and heated to 205° C. for melting Enzalutamide. The resultant reaction mixture is kept at ambient temperature to afford title compound. Yield: 190 mg
  • the Powder X-ray diffraction (PXRD) pattern of enzalutamide obtained in above example is in accordance with FIG. 2 .
  • Enzalutamide (200 mg) and formic acid (1 mL) were charged into a round bottom flask at 26° C. and heated to 70° C. for clear solution.
  • the resultant reaction mass was cooled to 0° C. and stirred at 0° C. for 15 minutes. Separated solid was collected by filtration, washed with pre cooled (3° C.) formic acid (0.5 mL) and dried at 70° C. under reduced pressure for 3 hours to afford the title compound. Yield: 105 mg
  • the Powder X-ray diffraction (PXRD) pattern of enzalutamide obtained in above example is in accordance with FIG. 3 .
  • the Powder X-ray diffraction (PXRD) pattern of enzalutamide obtained in above example is in accordance with FIG. 4 .
  • Enzalutamide (500 mg) and Methanol (5 mL) were charged into a round bottom flask at 26° C. and heated to 65° C. Filtered the solution to make it particle free and filterate was cooled to 30° C. Added 25 mg seed crystals of Form R1 and stirred at 25-30° C. for 15 minutes. The reaction mixture was further cooled to 0-5° C. and stirred for 1 hour. Separated solid was collected by filtration and dried at 70° C. under reduced pressure for 2 hours to afford the title compound. Yield: 320 mg

Landscapes

  • Engineering & Computer Science (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Multimedia (AREA)
  • Computer Security & Cryptography (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Business, Economics & Management (AREA)
  • Public Health (AREA)
  • General Business, Economics & Management (AREA)
  • Environmental & Geological Engineering (AREA)
  • Emergency Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
US14/427,527 2012-09-11 2013-09-11 Enzalutamide polymorphic forms and its preparation Abandoned US20150239848A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3772CH2012 2012-09-11
IN3772/CHE/2012 2012-09-11
PCT/IB2013/058455 WO2014041487A2 (fr) 2012-09-11 2013-09-11 Formes polymorphes d'enzalutamide et leur préparation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/058455 A-371-Of-International WO2014041487A2 (fr) 2012-09-11 2013-09-11 Formes polymorphes d'enzalutamide et leur préparation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/292,696 Continuation US9701641B2 (en) 2012-09-11 2016-10-13 Enzalutamide polymorphic forms and its preparation

Publications (1)

Publication Number Publication Date
US20150239848A1 true US20150239848A1 (en) 2015-08-27

Family

ID=50278792

Family Applications (3)

Application Number Title Priority Date Filing Date
US14/427,527 Abandoned US20150239848A1 (en) 2012-09-11 2013-09-11 Enzalutamide polymorphic forms and its preparation
US15/292,696 Expired - Fee Related US9701641B2 (en) 2012-09-11 2016-10-13 Enzalutamide polymorphic forms and its preparation
US15/611,486 Abandoned US20170267645A1 (en) 2012-09-11 2017-06-01 Enzalutamide polymorphic forms and its preparation

Family Applications After (2)

Application Number Title Priority Date Filing Date
US15/292,696 Expired - Fee Related US9701641B2 (en) 2012-09-11 2016-10-13 Enzalutamide polymorphic forms and its preparation
US15/611,486 Abandoned US20170267645A1 (en) 2012-09-11 2017-06-01 Enzalutamide polymorphic forms and its preparation

Country Status (14)

Country Link
US (3) US20150239848A1 (fr)
EP (1) EP2895464A4 (fr)
JP (1) JP2015534550A (fr)
KR (1) KR20150053963A (fr)
CN (1) CN104768935A (fr)
AU (1) AU2013316754A1 (fr)
BR (1) BR112015005404A2 (fr)
CA (1) CA2884640A1 (fr)
IL (1) IL237668A0 (fr)
IN (1) IN2015CH01921A (fr)
MX (1) MX2015003124A (fr)
RU (1) RU2015113434A (fr)
WO (1) WO2014041487A2 (fr)
ZA (1) ZA201502336B (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170190670A1 (en) * 2014-07-11 2017-07-06 Shilpa Medicare Limited Improved process for the preparation of enzalutamide
WO2018015958A1 (fr) 2016-07-21 2018-01-25 Hadasit Medical Research Services And Development Ltd. Antagonistes ou inhibiteurs d'ar pour utilisation dans le traitement du glioblastome
US11839689B2 (en) 2012-09-11 2023-12-12 Astellas Pharma Inc. Formulations of enzalutamide
WO2024153733A1 (fr) 2023-01-18 2024-07-25 Helm Ag Nanoparticules cristallines comprenant de l'enzalutamide
US12502357B2 (en) 2024-12-04 2025-12-23 Astellas Pharma Inc. Formulations of enzalutamide

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103910679B (zh) * 2014-04-23 2016-05-25 杭州新博思生物医药有限公司 一种恩杂鲁胺的制备方法
CN104356068A (zh) * 2014-10-30 2015-02-18 杭州新博思生物医药有限公司 恩杂鲁胺新晶型及其制备方法
US10499245B2 (en) 2015-04-02 2019-12-03 Samsung Electronics Co., Ltd. Method for performing multiple authentications within service registration procedure
CN106146403B (zh) * 2015-04-02 2018-11-20 正大天晴药业集团股份有限公司 一种恩杂鲁胺的纯化方法
CA2987563C (fr) * 2015-05-29 2024-04-09 Astellas Pharma Inc. Methode de production de forme cristalline d'enzalutamide
CN105030685B (zh) * 2015-07-21 2018-02-27 福格森（武汉）生物科技股份有限公司 一种恩杂鲁胺固体分散体口服制剂
WO2017041622A1 (fr) * 2015-09-10 2017-03-16 江苏恒瑞医药股份有限公司 Forme cristalline d'un inhibiteur de récepteur d'androgène et son procédé de préparation
JP7172997B2 (ja) 2017-04-28 2022-11-16 アステラス製薬株式会社 エンザルタミドを含有する経口投与用医薬組成物
ES2959954T3 (es) 2017-11-28 2024-02-29 Aarti Pharmalabs Ltd Proceso para la preparación de enzalutamida utilizando un nuevo intermedio
CZ2018234A3 (cs) 2018-05-21 2019-12-04 Zentiva Ks Zvýšení rozpustnosti a biodostupnosti enzalutamidu
BR112021015122A2 (pt) * 2019-02-01 2021-09-28 Chia Tai Tianqing Pharmaceutical Group Co., Ltd Cristal de composto de diariltio-hidantoína
CN110981812A (zh) * 2019-11-25 2020-04-10 奥锐特药业股份有限公司 一种无定形恩杂鲁胺的制备方法
CN111217757B (zh) * 2020-01-06 2021-03-19 武汉大学 一种恩杂鲁胺化合物及其药物组合物制剂
CN111303042A (zh) * 2020-03-25 2020-06-19 北京赛思源生物医药技术有限公司 一种恩杂鲁胺的新晶型

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020009494A1 (en) * 1997-08-11 2002-01-24 Curatolo William J. Solid pharmaceutical dispersions with enhanced bioavailability

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN191496B (fr) * 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
GB2383042A (en) * 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
US20050020675A1 (en) * 2003-02-21 2005-01-27 Parthasaradhi Reddy Bandi Bicalutamide polymorphs
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
RS52274B2 (sr) * 2005-05-13 2018-05-31 Univ California Jedinjenje diarilhidantoina
CA2648139A1 (fr) * 2006-03-29 2007-11-08 The Regents Of The University Of California Composes de diarylthiohydantoine et leur utilisation dans le traitement de troubles d'hyperproliferation
EP2538785B1 (fr) * 2010-02-24 2018-03-21 Medivation Prostate Therapeutics LLC Procédés pour la synthèse de composés diarylthiohydantoïnes et diarylhydantoïnes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020009494A1 (en) * 1997-08-11 2002-01-24 Curatolo William J. Solid pharmaceutical dispersions with enhanced bioavailability

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Calahan, Characterization of Amorphous Solid Dispersions of AMG 517 in HMPC-AS and Crystallization using Isothermal Microcalorimetry, April 4, 2011, pg. 1-128. *
Center of Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics Review, May 22, 2012, pg. 1-83. *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11839689B2 (en) 2012-09-11 2023-12-12 Astellas Pharma Inc. Formulations of enzalutamide
US12447128B2 (en) 2012-09-11 2025-10-21 Astellas Pharma Inc. Formulations of enzalutamide
US20170190670A1 (en) * 2014-07-11 2017-07-06 Shilpa Medicare Limited Improved process for the preparation of enzalutamide
WO2018015958A1 (fr) 2016-07-21 2018-01-25 Hadasit Medical Research Services And Development Ltd. Antagonistes ou inhibiteurs d'ar pour utilisation dans le traitement du glioblastome
US11478453B2 (en) 2016-07-21 2022-10-25 Hadasit Medical Research Services And Development Ltd. Treatment for glioblastoma
WO2024153733A1 (fr) 2023-01-18 2024-07-25 Helm Ag Nanoparticules cristallines comprenant de l'enzalutamide
US12502357B2 (en) 2024-12-04 2025-12-23 Astellas Pharma Inc. Formulations of enzalutamide

Also Published As

Publication number Publication date
EP2895464A4 (fr) 2016-06-15
WO2014041487A2 (fr) 2014-03-20
US20170267645A1 (en) 2017-09-21
BR112015005404A2 (pt) 2017-08-22
CA2884640A1 (fr) 2014-03-20
IL237668A0 (en) 2015-04-30
JP2015534550A (ja) 2015-12-03
KR20150053963A (ko) 2015-05-19
RU2015113434A (ru) 2016-11-10
CN104768935A (zh) 2015-07-08
EP2895464A2 (fr) 2015-07-22
ZA201502336B (en) 2016-02-24
US20170029380A1 (en) 2017-02-02
IN2015CH01921A (fr) 2016-07-01
US9701641B2 (en) 2017-07-11
WO2014041487A3 (fr) 2014-05-22
MX2015003124A (es) 2015-10-12
AU2013316754A1 (en) 2015-04-30

Similar Documents

Publication Publication Date Title
US9701641B2 (en) Enzalutamide polymorphic forms and its preparation
US9283210B2 (en) Amorphous mirabegron and processes for crystal forms of mirabegron
US20160272627A1 (en) Polymorphic forms of suvoroxant
US8779161B2 (en) Asenapine maleate
WO2011130615A2 (fr) Synthèse de lacosamide
US20160045470A1 (en) Amorphous solid dispersion of treprostinil diethanolamine
US9045473B2 (en) Forms of Apixaban
WO2016027243A1 (fr) Nouvelles formes solides de dimaléate d'afatinib
US20240082248A1 (en) Process for preparation of mavacamten and solid state forms thereof
WO2015011659A1 (fr) Formes polymorphes cristallines du régorafénib et méthodes de préparation de la forme polymorphe i du régorafénib
US9212172B2 (en) Preparation of crystalline bazedoxifene and its salts
WO2012106584A2 (fr) Sels de pitavastatine
US10301353B2 (en) Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib
US9981979B2 (en) Process for the formation of hydrocodone bitatrate
WO2011139414A2 (fr) Formes polymorphes de dexlansoprazole
TWI638810B (zh) 氘代咪唑酮化合物之晶型ｉ及其製備方法和用途
SPECIFICATION CRYSTALLINE FORMS OF MIRABEGRON AND PROCESS FOR THEIR PREPARATION

Legal Events

Date Code Title Description
AS Assignment

Owner name: DR. REDDY'S LABORATORIES LIMITED, INDIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PEDDY, VISHWESHWAR;BOGE, RAJESHAM;MADIVADA, LOKESWARA RAO;REEL/FRAME:036705/0350

Effective date: 20150618

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION